Thomas Gabrielczyk, Author at European Biotechnology Network

About Thomas Gabrielczyk

This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1163 entries already.

Entries by Thomas Gabrielczyk

Zambon heading to US market with 500m acquisition

26th July 2019/in News/by Thomas Gabrielczyk

Zambon is set to acquire respiratory company Breath Therapeutics for up to 500m to complement its respiratory pipeline and get access to the US market.

Gut microbiome boosts muscle strength

25th July 2019/in News/by Thomas Gabrielczyk

Swedish researchers have demonstrated that the gut microbiome can significantly affect the proper development and strength of skeletal muscle.

Curetis lower respiratory tract panel ready for FDA clearance

23rd July 2019/in News/by Thomas Gabrielczyk

Molecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections.

Merck and Broad Institute announce CRISPR license agreement

22nd July 2019/in News/by Thomas Gabrielczyk

Merck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing.

Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal

1st July 2019/in News/by Thomas Gabrielczyk

Boehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay $40m upfront and […]